Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 47.89% | 9.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 47.89% | 9.01% | |||
| Cost of Revenue | 5.43% | -6.05% | |||
| Gross Profit | 5.01% | 9.14% | |||
| SG&A Expenses | -0.48% | 14.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.38% | 3.49% | |||
| Operating Income | 2.42% | -2.94% | |||
| Income Before Tax | 3.53% | -12.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.53% | -12.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.53% | -12.57% | |||
| EBIT | 2.42% | -2.94% | |||
| EBITDA | 2.61% | -2.70% | |||
| EPS Basic | 9.96% | -9.67% | |||
| Normalized Basic EPS | 9.97% | -9.67% | |||
| EPS Diluted | 9.96% | -9.67% | |||
| Normalized Diluted EPS | 9.97% | -9.67% | |||
| Average Basic Shares Outstanding | 7.15% | 2.64% | |||
| Average Diluted Shares Outstanding | 7.15% | 2.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||